← FDA DRUG APPROVALS

FDA ANDA · ANDA216156

POTASSIUM CHLORIDE

Sponsor: AJENAT PHARMS

APPLICATION
ANDA216156
TYPE
ANDA
ORIGINAL APPROVAL
2023-03-07
LATEST ACTION
2023-03-07
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

POTASSIUM CHLORIDEPrescription
POTASSIUM CHLORIDE 40MEQ/15ML · SOLUTION · ORAL
POTASSIUM CHLORIDEPrescription
POTASSIUM CHLORIDE 20MEQ/15ML · SOLUTION · ORAL

Approval history

2023-03-07UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →